Arcellx (ACLX) Free Cash Flow Growth (3y) (2024 - 2025)
Arcellx (ACLX) Free Cash Flow Growth (3y) (2024 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | 31.42% |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | -29.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -29.14% |
| Sep 30, 2025 | -44.28% |
| Jun 30, 2025 | -19.99% |
| Mar 31, 2025 | -24.59% |
| Dec 31, 2024 | -30.26% |
| Sep 30, 2024 | 73.81% |
| Jun 30, 2024 | -48.84% |
| Mar 31, 2024 | -57.87% |